Biorepository to Support Research in Kidney Diseases
3 other identifiers
observational
1,000
1 country
2
Brief Summary
To support advances in the understanding of pathophysiology and therapies of kidney diseases by creating a BioBank of kidney tissue, DNA, plasma, and urine from patients with kidney diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 8, 2020
CompletedFirst Posted
Study publicly available on registry
April 13, 2020
CompletedStudy Start
First participant enrolled
July 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2035
August 13, 2025
August 1, 2025
10 years
April 8, 2020
August 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Histological diagnosis
Histological diagnosis of kidney disease determined by evaluation by renal pathologists
5 years
Secondary Outcomes (1)
Occurrence of chronic kidney disease, end stage kidney disease or death
10 years
Study Arms (1)
Biorepository
Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
Eligibility Criteria
The biorepository is a prospective cohort study of subjects with kidney diseases, who are scheduled to undergo a kidney biopsy at Yale New Haven Hospital (York St. or St. Raphael's campus) as part of the routine clinical care and agree to participate in this study.
You may qualify if:
- Patients scheduled to undergo a clinically indicated kidney biopsy
- English or Spanish speaking
You may not qualify if:
- Under 18 years or age
- Known pregnancy
- Additional vulnerable individuals (incarcerated, institutionalized, or otherwise unable to participate in the study)
- Inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Yale New Haven Hospital, York Street Campus
New Haven, Connecticut, 06510, United States
Yale New Haven Hospital Saint Raphael Campus
New Haven, Connecticut, 06511, United States
Biospecimen
Blood (serum, plasma, and DNA extraction), urine samples, kidney tissue sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dennis G Moledina, MD
Yale University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2020
First Posted
April 13, 2020
Study Start
July 28, 2020
Primary Completion (Estimated)
August 1, 2030
Study Completion (Estimated)
August 1, 2035
Last Updated
August 13, 2025
Record last verified: 2025-08